Come November, we will know how Day One Biopharmaceuticals Inc.'s (DAWN) first and only marketed drug, Ojemda, fared in its first full quarter on the market.
Ojemda was granted accelerated approval by the FDA for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation on Apr.23, 2024.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com